Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
August 17 2021 - 7:00AM
Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development
and manufacturing organization (CDMO) dedicated to solving complex
formulation and manufacturing challenges for companies developing
oral solid dose drug products, today announced that company
management will host a webcast to discuss the company’s recently
announced acquisition of IRISYS, a San Diego-based CDMO that
possesses capabilities that complement and expand those of Recro.
The webcast will be held at 11:00 a.m. Eastern on Thursday, August
19, 2021.
During the event, Recro’s management team will
discuss the rationale for its acquisition of IRISYS and provide an
overview of the transaction's expected impact on the company’s
ongoing growth strategy. The discussion will highlight Recro’s
operations on both the East and West Coast of the U.S., as well as
the organization’s expanded global client base and enhanced
capabilities now spanning pre-Investigational New Drug (IND)
development to commercial manufacturing and packaging for a wide
range of dosage forms.
To access the webcast, please do so by visiting
the “Events” page in the Investor section of the Company’s
website, www.recrocdmo.com. In addition, an archived webcast
will be available on the Company’s website approximately two hours
after the event and will be available for 30 days.
About RecroRecro (NASDAQ: REPH)
is a contract development and manufacturing organization (CDMO)
with capabilities from early feasibility to commercial
manufacturing. With an expertise in solving complex manufacturing
problems, Recro is a CDMO providing oral solid dosage form
development, end-to-end regulatory support, clinical and commercial
manufacturing, and packaging and logistics services to the global
pharmaceutical market.
In addition to our experience in handling DEA
controlled substances and developing and manufacturing modified
release oral solid dosage forms, Recro has the expertise to deliver
on our clients’ pharmaceutical development and manufacturing
projects, regardless of complexity level. We do all of this in our
best-in-class facilities, which total 120,000 square feet, in
Gainesville, Georgia.
For more information about Recro’s CDMO
solutions, visit recrocdmo.com.
Forward-Looking StatementsThis
press release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. These statements, among
other things, the Company’s expectations regarding, the potential
benefits of the acquisition of IRISYS, and other statements. The
words “anticipate”, “believe”, “could”, “estimate”, “upcoming”,
“expect”, “intend”, “may”, “plan”, “predict”, “project”, “will” and
similar terms and phrases may be used to identify forward-looking
statements in this press release. Factors that could cause the
Company’s actual outcomes to differ materially from those expressed
in or underlying these forward-looking statements include risks
that the results and potential of the combined business and the
combination IRISYS’ business with the Company’s business may not be
as anticipated; the potential impact of the IRISYS acquisition to
the Company's growth strategy; the ongoing economic and social
consequences of the COVID-19 pandemic, including any adverse impact
on the customer ordering patterns or inventory rebalancing or
disruption in raw materials or supply chain; demand for the
Company’s services, which depends in part on customers’ research
and development and the clinical plans and market success of their
products; customers’ changing inventory requirements and
manufacturing plans; customers and prospective customers decisions
to move forward with the Company’s manufacturing services; the
average profitability, or mix, of the products the Company
manufactures; the Company’s ability to enhance existing or
introduce new services in a timely manner; fluctuations in the
costs, availability, and suitability of the components of the
products the Company manufactures, including active pharmaceutical
ingredients, excipients, purchased components and raw materials, or
the Company’s customers facing increasing or new competition. These
forward-looking statements should be considered together with the
risks and uncertainties that may affect our business and future
results presented herein along with those risks and uncertainties
discussed in our filings with the Securities and Exchange
Commission at www.sec.gov. These forward-looking statements are
based on information currently available to us, and we assume no
obligation to update any forward-looking statements except as
required by applicable law.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Ryan D. Lake (CFO)
Recro
770-531-8365
ryan.lake@recroCDMO.com
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Recro Pharma (NASDAQ:REPH)
Historical Stock Chart
From Apr 2023 to Apr 2024